Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results, Hits Estimates

Amylyx Pharmaceuticals (NASDAQ:AMLX) posted its earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• Avexitide’s Phase III LUCIDITY trial met its primary and all secondary endpoints, including a 55% reduction in the composite rate of level 2 and level 3 hypoglycemic events versus placebo, with a favorable safety profile. Amylyx remains on track to submit an NDA by year-end and is preparing for a potential 2027 launch, subject to FDA review.
• An oversubscribed equity offering generated $545 million in net proceeds, bringing cash and cash equivalents to $768 million at quarter-end. Management said the funds support NDA preparation, launch readiness, and pipeline development.
• The company estimates about 160,000 people in the U.S. live with PBH and reports growing physician interest in treatment options; a PBH-specific ICD-10 code took effect in October. These market-size and demand assessments are based on Amylyx’s analyses and research.
• Operating expenses rose 38% year over year to $49.7 million, reflecting higher trial spending and pre-commercialization costs; stock-based compensation also increased. The higher spending comes as Amylyx scales its commercial organization ahead of a possible launch.
• Beyond avexitide, Amylyx is targeting a 2027 IND filing for AMX0318, while its AMX0114 ALS trial has advanced to enrollment in its fourth dose cohort. The company also reported progress on a research collaboration, but did not provide new efficacy results for these programs.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock traded up $1.12 during trading hours on Friday, reaching $28.74. 443,438 shares of the stock were exchanged, compared to its average volume of 1,621,026. The stock has a market cap of $3.20 billion, a P/E ratio of -20.09 and a beta of -0.09. Amylyx Pharmaceuticals has a 52-week low of $10.83 and a 52-week high of $41.14. The firm’s 50 day moving average is $30.15 and its 200 day moving average is $20.35.

Wall Street Analysts Forecast Growth

AMLX has been the subject of several analyst reports. Stifel Nicolaus set a $45.00 price objective on Amylyx Pharmaceuticals in a report on Thursday. HC Wainwright raised their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Tuesday. Robert W. Baird boosted their price target on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Finally, Mizuho upped their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.14.

Key Headlines Impacting Amylyx Pharmaceuticals

Here are the key news stories impacting Amylyx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $55 price target, indicating substantial potential upside relative to the recently reported share price. The firm forecasts continued quarterly losses through 2027, but expects them to narrow from $0.38 per share in Q1 to $0.32 in Q4. MarketBeat Amylyx analyst coverage
• Neutral Sentiment: Amylyx reported a third-quarter loss of $0.38 per share, matching analysts’ consensus estimate. The result met expectations, but the company remains loss-making, limiting the earnings report’s near-term directional signal. Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results

Insiders Place Their Bets

In related news, insider Gina Mazzariello sold 9,536 shares of Amylyx Pharmaceuticals stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $32.46, for a total value of $309,538.56. Following the sale, the insider directly owned 190,838 shares in the company, valued at $6,194,601.48. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO James Frates sold 10,810 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $32.36, for a total transaction of $349,811.60. Following the transaction, the chief financial officer directly owned 233,625 shares in the company, valued at approximately $7,560,105. This trade represents a 4.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 60,374 shares of company stock valued at $1,815,257 over the last 90 days. 10.90% of the stock is owned by corporate insiders.

Amylyx Pharmaceuticals Company Profile